Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance

WSJ04:02

Gilead Sciences turned a profit in the first quarter and maintained its annual performance forecast.

On April 25, Gilead Sciences, a USA pharmaceutical company, announced that its revenue for the first quarter was $6.7 billion, while the market expectation was $6.8 billion; the Net income was $1.315 billion, compared to a loss of 4.17 billion yuan in the same period last year, mainly related to write-offs; adjusted earnings per share were $1.81, while market expectations were $1.79. The group maintained its annual performance forecast, with revenue projected between $28.2 billion and $28.6 billion, and adjusted earnings per share between $7.7 and $8.1. This forecast has taken into account the tariff effects of USA President Trump.

Gelonghui Finance23minutes ago

Earnings Call Summary | Gilead Sciences(GILD.US) Q1 2025 Earnings Conference

Futu News08:06 · Conference Call

Gilead Sciences Highlights Potential FDA Approval for Lenacapavir in June 2025

Seeking Alpha08:02

Research Alert: CFRA Keeps Hold Opinion On Shares Of Gilead Sciences, Inc.

MT Newswires06:35

Research Alert: Mixed Q1 Performance, 2025 Product Sales And Adjusted Eps Guidance Maintained

MT Newswires05:25 · Ratings